|42.57||+0.2600||+0.61%||Vol 11.94M||1Y Perf 20.03%|
|Apr 22nd, 2021 16:00 DELAYED|
|-0.12 -0.28%||- -|
|Target Price||43.79||Analyst Rating||Strong Buy 1.28|
|Potential %||2.87||Finscreener Ranking||★+ 44.31|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 46.10|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★ 44.16|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||60.47B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||97.66||Earnings Date||28th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||28th Apr 2021|
|Estimated EPS Next Report||0.30|
|EPS Growth Next 5 Years %||9.30|
|Avg. Weekly Volume||9.74M|
|Avg. Monthly Volume||6.79M|
|Avg. Quarterly Volume||8.94M|
Boston Scientific Corporation (NYSE: BSX) stock closed at 42.57 per share at the end of the most recent trading day (a 0.61% change compared to the prior day closing price) with a volume of 12.02M shares and market capitalization of 60.47B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 38000 people. Boston Scientific Corporation CEO is Michael F. Mahoney.
The one-year performance of Boston Scientific Corporation stock is 20.03%, while year-to-date (YTD) performance is 18.41%. BSX stock has a five-year performance of 115.44%. Its 52-week range is between 32.99 and 42.8, which gives BSX stock a 52-week price range ratio of 97.66%
Boston Scientific Corporation currently has a PE ratio of -511.40, a price-to-book (PB) ratio of 3.79, a price-to-sale (PS) ratio of 7.88, a price to cashflow ratio of 38.40, a PEG ratio of 2.32, a ROA of -0.36%, a ROC of 17.62% and a ROE of -0.76%. The company’s profit margin is -1.33%, its EBITDA margin is 14.20%, and its revenue ttm is $7.37 Billion , which makes it $5.19 revenue per share.
Of the last four earnings reports from Boston Scientific Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.30 for the next earnings report. Boston Scientific Corporation’s next earnings report date is 28th Apr 2021.
The consensus rating of Wall Street analysts for Boston Scientific Corporation is Strong Buy (1.28), with a target price of $43.79, which is +2.87% compared to the current price. The earnings rating for Boston Scientific Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Boston Scientific Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Boston Scientific Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 9.59, ATR14 : 0.98, CCI20 : 182.02, Chaikin Money Flow : 0.35, MACD : 1.01, Money Flow Index : 85.17, ROC : 9.29, RSI : 76.82, STOCH (14,3) : 94.60, STOCH RSI : 1.00, UO : 67.78, Williams %R : -5.40), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Boston Scientific Corporation in the last 12-months were: Arthur C. Butcher (Option Excercise at a value of $173 310), Arthur C. Butcher (Sold 26 578 shares of value $1 052 852 ), Daniel J. Brennan (Option Excercise at a value of $177 897), Daniel J. Brennan (Sold 63 531 shares of value $2 415 321 ), David A. Pierce (Option Excercise at a value of $0), David A. Pierce (Sold 54 948 shares of value $2 121 049 ), Desiree Ralls-Morrison (Option Excercise at a value of $0), Desiree Ralls-Morrison (Sold 1 182 shares of value $46 098 ), Edward F. Mackey (Option Excercise at a value of $0), Eric Francis Yves Thepaut (Option Excercise at a value of $241 677), Eric Francis Yves Thepaut (Sold 28 883 shares of value $1 116 354 ), Ian T. Meredith (Option Excercise at a value of $0), Jeffrey B. Mirviss (Option Excercise at a value of $933 812), Jeffrey B. Mirviss (Sold 170 864 shares of value $6 949 592 ), Jodi Euerle Eddy (Option Excercise at a value of $0), Jodi Euerle Eddy (Sold 15 500 shares of value $604 258 ), John Bradley Sorenson (Option Excercise at a value of $0), John Bradley Sorenson (Sold 7 500 shares of value $292 971 ), Jonathan Monson (Option Excercise at a value of $0), Joseph M. Fitzgerald (Option Excercise at a value of $555 902), Joseph M. Fitzgerald (Sold 77 640 shares of value $3 164 653 ), Maulik Nanavaty (Option Excercise at a value of $118 248), Maulik Nanavaty (Sold 38 000 shares of value $1 537 164 ), Meghan Scanlon (Option Excercise at a value of $0), Michael F. Mahoney (Option Excercise at a value of $0), Michael F. Mahoney (Sold 259 207 shares of value $9 087 227 ), Scott Olson (Option Excercise at a value of $0), Scott Olson (Sold 1 400 shares of value $52 283 ), Wendy Carruthers (Option Excercise at a value of $0), Wendy Carruthers (Sold 10 200 shares of value $399 401 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.